Swiss drug maker NovImmune has begun a proof-of-concept study to evaluate NI-0801 in patients with primary biliary cirrhosis.

NI-0801 is a fully human monoclonal antibody that neutralises CXCL10 / interferon-gamma-inducible protein-10 (IP-10) chemokine.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Two previous Phase I trials have demonstrated that the drug is safe and well tolerated when given to healthy volunteers.

Principal investigator David Adams said that the therapeutic approach of neutralising CXCL10 / IP-10 with NI-0801 will offer great benefits to the large and therapeutically ill-served primary biliary cirrhosis patient population.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
YPrime won the Innovation award for AI in Clinical Trials and the Environmental award for Sustainable Trials, thanks to its eCOA, IRT and eConsent platforms. Explore how purpose-built AI, paperless workflows and circular hardware practices are reshaping timelines, data quality and ESG performance in clinical research.

Discover the Impact